Formation goes all in on AI, wins giant series D investment

27 June 2024

AI-focused start-up Formation Bio has raised $372 million in a series D financing.

The round was led by a16z, with significant participation from Sanofi (Nasdaq: SNY) as well as Sequoia, Thrive, Emerson Collective, and others.

Scott Kupor, managing partner at a16z, and Alfred Lin, partner at Sequoia, will join the board of directors at the firm, which leverages advances in artificial intelligence to enhance drug development efficiency.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology